Overview

DMT310-009 Topical in the Treatment of Acne Vulgaris

Status:
Recruiting
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
Phase:
Phase 3
Details
Lead Sponsor:
Dermata Therapeutics